Paradigm Therapeutics nominated for Prix Galien award for Zorblesia
Biopharmaceutical firm Paradigm Therapeutics earned a nomination for the 2026 Prix Galien USA Best Start Up award for its topical epidermolysis bullosa treatment candidate Zorblesia
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.